Results from an ongoing phase 1 study indicate ACDT-301 (camidanlumab tesirine) is well-tolerated in patients with relapsed or refractory CD25-positive acute leukemia Meeting Abstract


Authors: Goldberg, A. D.; Tallman, M. S.; Solh, M. M.; Ungar, D.; Rizzieri, D. A.; Walter, R. B.; Spira, A. I.; Chung, K. Y.; Stock, W.; He, S.; Boni, J.; Atallah, E.
Abstract Title: Results from an ongoing phase 1 study indicate ACDT-301 (camidanlumab tesirine) is well-tolerated in patients with relapsed or refractory CD25-positive acute leukemia
Meeting Title: 59th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 130
Issue: Suppl. 1
Meeting Dates: 2017 Dec 9-12
Meeting Location: Atlanta, GA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2017-12-07
Language: English
ACCESSION: WOS:000432419406295
PROVIDER: wos
Notes: Meeting Abstract: 2662 -- Source: Wos
MSK Authors
  1. Martin Stuart Tallman
    443 Tallman